Displaying 97 - 108 of 452
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
6

Opella: MASLD: Early screening, Treatment Strategies, and Quality of Life – Insights from New Clinical Evidence - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
Metabolism, Alcohol & Toxicity
5

Novo Nordisk: Addressing MASH as a liver manifestation of the metabolic disease - EASL SLD Summit 2025

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
5

LUNCH FORUM: The non-invasive assessment of fibrosis in biliary diseases - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
General Hepatology
7

Round table with industry: Future therapies in biliary fibrosis - EASL Monothematic Conference - Biliary Fibrosis 2023

View
Displaying 97 - 108 of 452